Teva’s stock price isn’t just “down.” It’s just about down to the levels it saw on the last day of Jeremy Levin’s chief exec stint in 2014. And some are wondering just how responsible current CEO Erez Vigodman is for the decline.
Vigodman, of course, got credit for previously sending shares up by 40%, Israeli newspaper Globes points out; they peaked in the summer of 2015, when Teva announced its $40 billion acquisition of Allergan’s generics unit.
Since then, though, things have changed. For one, investor sentiment has soured on the Allergan deal, which now looks as though it may have been overpriced. “At $40 billion, could Teva not have bought businesses with higher profit margins?” one industry source asked Globes.
Then there’s Teva’s other recent M&A move–a buy of Mexico’s Rimsa that went so wrong that Rimsa’s founders sued the company. The lawsuit accuses Teva of concocting false accusations of fraud to wriggle out of the deal. (Teva, for its part, says it was misled and that Rimsa itself committed violations.)
Fair or not, “some investors are connecting the two things,” Leader Capital Markets analyst Sabina Podval Levy told the publication–and they’re worried about a problem with Teva’s M&A engine.
The way Teva sees it, under Vigodman’s leadership, “we have delivered on our promises and continued to execute a growth strategy that we believe will deliver value for patients and shareholders alike,” a spokeswoman told FiercePharma via email.
And as Globes points out, two of the biggest factors affecting Teva’s stock are out of Vigodman’s control. Price erosion is hurting the entire generics industry, and generics challengers are taking on star product Copaxone in a court battle analysts widely expect Teva to lose.
So what can Vigodman do to restore the faith in the meantime? Give the market a signal that Teva knows what it’s doing, Globes suggests, whether it’s a plan for Actavis cost-cutting that will justify the deal price, proof that the Rimsa debacle was a one-time blip, or–perhaps most importantly–evidence that Teva’s skipper is in control of what goes down at the drugmaker.
By Carly Helfand
Source: Fierce Pharma
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
